Project Grant K23HL183757
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $385K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $354,982 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms driving lung fibrosis following severe viral respiratory infections. The research dissects how aberrant immune-epithelial interactions perpetuate post-viral lung damage distinct from idiopathic pulmonary fibrosis. The work focuses on three objectives: defining mechanisms that sustain...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $777,419 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the muco-obstructive mechanisms underlying bronchiectasis and identify novel therapeutic targets. The research examines bronchiectasis pathogenesis through a revised conceptual model that integrates airway epithelial hypoxia, mucus hyperconcentration, osmotic pressure-driven airway...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $1,579,157 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate conformational changes in fibronectin as a therapeutic target in idiopathic pulmonary fibrosis. The research examines stretch-dependent conformational changes in fibronectin within active fibrogenic regions of lung tissue from IPF patients, tests the molecular mechanisms by which stretch-induced fibronectin...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung and Blood Institute awarded Cincinnati Children's Hospital Medical Center $3.193 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to non-invasively quantify alveolar remodeling in cystic fibrosis lung disease using hyperpolarized xenon MRI. The research aims to establish the prevalence and short-term trajectories of emphysema-like remodeling in people with cystic fibrosis receiving CFTR modulator therapy. Cincinnati Children's...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $2.31 million on September 15, 2025, to develop and apply computational methods integrating metabolomic and genomic data to interrogate the pathogenesis of chronic obstructive pulmonary disease under the Cardiovascular Diseases Research program (CFDA 93.837). Performance runs through May 31, 2029, in Charlottesville, Virginia. The funded work centers on expanding and refining the MetaboxCan analytical method,...